← Back to results Economic Evaluation of Bruton’s Tyrosine Kinase Inhibitors for Chronic Lymphocytic Leukaemia in South Africa Rochelle Woudberg & Edina Sinanovic
What the paper says Zanubrutinib may be a cost-saving and clinically superior treatment option for both untreated and relapsed/refractory CLL compared to ibrutinib in South Africa's public healthcare system. Its dominance is driven by lower acquisition and adverse event costs, paired with favourable survival and quality-of-life outcomes. Acalabrutinib may also represent a cost-effective alternative compared to ibrutinib, providing meaningful clinical benefit at acceptable additional cost. These results support the prioritisation of zanubrutinib for public sector access and reimbursement, while highlighting acalabrutinib's value in selected patient scenarios.
Open paper page → Cite
Cite this paper https://doi.org/https://doi.org/10.1007/s40258-026-01031-9 Copy URL
Or copy a formatted citation
BibTeX RIS APA Chicago Link
@article{rochelle2026,
title = {{Economic Evaluation of Bruton’s Tyrosine Kinase Inhibitors for Chronic Lymphocytic Leukaemia in South Africa}},
author = {Rochelle Woudberg & Edina Sinanovic},
journal = {Applied Health Economics and Health Policy},
year = {2026},
doi = {https://doi.org/https://doi.org/10.1007/s40258-026-01031-9},
} TY - JOUR
TI - Economic Evaluation of Bruton’s Tyrosine Kinase Inhibitors for Chronic Lymphocytic Leukaemia in South Africa
AU - Woudberg, Rochelle
AU - Sinanovic, Edina
JO - Applied Health Economics and Health Policy
PY - 2026
ER - Rochelle Woudberg & Edina Sinanovic (2026). Economic Evaluation of Bruton’s Tyrosine Kinase Inhibitors for Chronic Lymphocytic Leukaemia in South Africa. *Applied Health Economics and Health Policy*. https://doi.org/https://doi.org/10.1007/s40258-026-01031-9 Rochelle Woudberg & Edina Sinanovic. "Economic Evaluation of Bruton’s Tyrosine Kinase Inhibitors for Chronic Lymphocytic Leukaemia in South Africa." *Applied Health Economics and Health Policy* (2026). https://doi.org/https://doi.org/10.1007/s40258-026-01031-9. Economic Evaluation of Bruton’s Tyrosine Kinase Inhibitors for Chronic Lymphocytic Leukaemia in South Africa
Rochelle Woudberg & Edina Sinanovic · Applied Health Economics and Health Policy · 2026
https://doi.org/https://doi.org/10.1007/s40258-026-01031-9 Copy
Paste directly into BibTeX, Zotero, or your reference manager.
Flag this paper Evidence weight Balanced mode · F 0.40 / M 0.15 / V 0.05 / R 0.40
F · citation impact 0.50 × 0.4 = 0.20 M · momentum 0.50 × 0.15 = 0.07 V · venue signal 0.50 × 0.05 = 0.03 R · text relevance † 0.50 × 0.4 = 0.20
† Text relevance is estimated at 0.50 on the detail page — for your query’s actual relevance score, open this paper from a search result.